Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.71 |
| ▸ | BTK | Q06187 | 12/20 | 0.69 |
| ▸ | ITK | Q08881 | 4/20 | 0.69 |
| ▸ | TEC | P42680 | 3/20 | 0.69 |
| ▸ | BMX | P51813 | 3/20 | 0.69 |
| ▸ | TXK | P42681 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | BLK | P51451 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.69 |
| ▸ | LATS1 | O95835 | 1/20 | 0.69 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613606 | 0.89 | EGFR (0.90) | EGFRBTKITKTECBMX | |
| SCHEMBL1612532 | 0.87 | EGFR (0.60) | EGFRBTKITKTECBMX | |
| SCHEMBL1613903 | 0.86 | BTK (0.58) | EGFRBTKITKTECBMX | |
| SCHEMBL19413809 | 0.85 | BTK (0.77) | EGFRBTKITKTECBMX | |
| SCHEMBL28399585 | 0.83 | EGFR (1.00) | EGFRBTKITKTECBMX | |
| SCHEMBL19763387 | 0.83 | EGFR (1.00) | EGFRBTKITKTECBMX | |
| SCHEMBL22625456 | 0.82 | BTK (0.69) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL2244865 | 0.82 | BTK (1.00) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL201641 | 0.82 | BTK (1.00) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL201859 | 0.82 | BTK (1.00) | EGFRBTKITKTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046964-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 947/4885BTK 2/4885ITK 390/4885 |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | EGFR 947/4885BTK 2/4885ITK 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.